Investment Rating - The investment rating for the company is upgraded to "Accumulate" [1] Core Views - The company has shown improvement in profitability in Q1 2025, with expectations for a turnaround in operations in the second half of 2025 [3][11] - The average price of lithium iron phosphate (LiFePO4) decreased significantly in 2024, leading to substantial losses, but the price has started to recover in Q1 2025, resulting in a reduction of losses [3][11] - The company is expected to achieve a single-quarter profit in H2 2025 due to improved pricing of high-end products and structural optimization [3] Financial Performance Summary - Total revenue for 2023 was 16,973 million yuan, with a projected decline of 55.15% in 2024, followed by a recovery of 14.89% in 2025 [1][12] - The net profit attributable to the parent company was -1,636.24 million yuan in 2023, with a forecasted loss of -1,337.65 million yuan in 2024, and a projected profit of 269.44 million yuan in 2026 [1][12] - The earnings per share (EPS) is expected to improve from -5.84 yuan in 2023 to 2.18 yuan in 2027 [1][12] Operational Insights - The company experienced a slight increase in shipment volume in 2024, with expectations for a significant increase in 2025 [10] - Cost control measures have been strengthened, leading to a reduction in inventory levels [11] - The company’s operating cash flow was significantly impacted in 2024, but is expected to improve in the coming years [11] Market Data - The closing price of the company's stock is 27.44 yuan, with a market capitalization of 7,688.36 million yuan [7] - The company has a price-to-book ratio of 1.43 and a debt-to-asset ratio of 61.71% [8][12]